Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,291,028 papers from all fields of science
Search
Sign In
Create Free Account
BH 3
Known as:
4-(1-aminoethyl)-2,6-bis(1,1-dimethylethyl)phenol
, BH-3
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Butylated Hydroxytoluene
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic
S. Sarkar
,
B. Quinn
,
+8 authors
P. Fisher
OncoTarget
2015
Corpus ID: 1509934
Despite recent advances, treatment options for advanced prostate cancer (CaP) remain limited. We are pioneering approaches to…
Expand
2015
2015
Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo
G. Karpel-Massler
,
C. Shu
,
+8 authors
M. Siegelin
OncoTarget
2015
Corpus ID: 15394358
Despite great efforts taken to advance therapeutic measures for patients with glioblastoma, the clinical prognosis remains grim…
Expand
2014
2014
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer
W. Schelman
,
T. Mohammed
,
+8 authors
Glenn Liu
Investigational new drugs
2014
Corpus ID: 28827975
SummaryBackground. A phase I, dose-escalation study of AT-101 with cisplatin and etoposide was conducted to determine the maximum…
Expand
2013
2013
The novel BH-3 mimetic apogossypolone induces Beclin-1- and ROS-mediated autophagy in human hepatocellular carcinoma cells
P. Cheng
,
Z. Ni
,
+7 authors
J. Lian
Cell Death and Disease
2013
Corpus ID: 811528
Correction to: Cell Death and Disease (2013) 4, e489; doi:10.1038/cddis.2013.17; published online 7 February 2013 Since the…
Expand
2013
2013
Combination treatments with ABT‐263 and an immunotoxin produce synergistic killing of ABT‐263‐resistant small cell lung cancer cell lines
Abid R Mattoo
,
D. FitzGerald
International Journal of Cancer
2013
Corpus ID: 13775528
Synergistic killing was achieved when Small Cell Lung Cancer (SCLC) cell lines were incubated with ABT‐263 and an immunotoxin…
Expand
2012
2012
Gefitinib Analogue V1801 Induces Apoptosis of T790M EGFR-Harboring Lung Cancer Cells by Up-Regulation of the BH-3 Only Protein Noxa
Bo Zhang
,
Jiao Jiao
,
+5 authors
Guang-Biao Zhou
PLoS ONE
2012
Corpus ID: 15750395
Treatment of non-small cell lung cancer (NSCLC) with drugs targeting the epidermal growth factor receptor (EGFR), e.g., gefitinib…
Expand
Highly Cited
2011
Highly Cited
2011
Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1.
Luke R E Harrison
,
D. Micha
,
+10 authors
C. Dive
Journal of Clinical Investigation
2011
Corpus ID: 44385248
Solid tumors contain hypoxic regions in which cancer cells are often resistant to chemotherapy-induced apoptotic cell death…
Expand
Review
2010
Review
2010
Apoptosis in pre-Bilaterians: Hydra as a model
Margherita Lasi
,
C. N. David
,
A. Böttger
Apoptosis
2010
Corpus ID: 31462201
Hydra is a member of the ancient metazoan phylum Cnidaria and is an especially well investigated model organism for questions of…
Expand
Review
2009
Review
2009
Emerging role of tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL) as a key regulator of inflammatory responses
A. Collison
,
P. Foster
,
J. Mattes
Clinical and Experimental Pharmacology and…
2009
Corpus ID: 27516445
1. Tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL) induces apoptosis in tumour cells while leaving most non…
Expand
Review
2003
Review
2003
Mitochondrial membrane permeabilisation by Bax/Bak.
M. Degli Esposti
,
C. Dive
Biochemical and Biophysical Research…
2003
Corpus ID: 25811778
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE